pyoderma gangrenosum

From Aaushi
Jump to navigation Jump to search

Etiology

Epidemiology

  • mean age 52 years, 32% > 65 years[13]
  • 75% women

Pathology

Clinical manifestations

* images[10][11]

Diagnostic criteria

Laboratory

Diagnostic procedures

Radiology

Differential diagnosis

Management

More general terms

More specific terms

Additional terms

References

  1. Harrison's Principles of Internal Medicine, 13th ed. Isselbacher et al (eds), McGraw-Hill Inc. NY, 1994, pg 307
  2. Color Atlas & Synopsis of Clinical Dermatology, Common & Serious Diseases, 3rd ed, Fitzpatrick et al, McGraw Hill, NY, 1997, pg 396-97
  3. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 171, 174
  4. 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 Medical Knowledge Self Assessment Program (MKSAP) 11, 15, 16, 17, 18. American College of Physicians, Philadelphia 1998, 2009, 2012, 2015, 2018
  5. Callen JP and Jackson JM, Pyoderma gangrenosum: an update Rheum Dis Clin of North Am 2007 33:787 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18037117
  6. 6.0 6.1 Brenner M et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009 Nov; 161:1199. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19673875
  7. Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol. 2009 Sep;23(9):1008-17 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19470075
  8. Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol. 2010 Apr;62(4):646-54 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20227580
  9. 9.0 9.1 9.2 Ormerod AD et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: Results of the STOP GAP randomised controlled trial. BMJ 2015; 350:h2958 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26071094
  10. 10.0 10.1 Jackson JM, James WD (images) Medscape: Pyoderma Gangrenosum http://emedicine.medscape.com/article/1123821-overview
  11. 11.0 11.1 DermNet NZ. Pyoderma gangrenosum (images) http://www.dermnetnz.org/reactions/pyoderma-gangrenosum.html
  12. Dabade TS, Davis MD. Diagnosis and treatment of the neutrophilic dermatoses (pyoderma gangrenosum, Sweet's syndrome). Dermatol Ther. 2011 Mar-Apr;24(2):273-84 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21410617
  13. 13.0 13.1 13.2 Ashchyan HJ, Butler DC, Nelson CA et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. JAMA Dermatol 2018 Apr 1; 154:409. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29450453 https://jamanetwork.com/journals/jamadermatology/fullarticle/2672271
  14. Pompeo MQ. Pyoderma Gangrenosum:Recognition and Management. Wounds. 2016 Jan;28(1):7-13. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26779805 Free Article
  15. Herberger K, Dissemond J, Hohaus K et al Treatment of pyoderma gangrenosum: retrospective multicentre analysis of 121 patients. Br J Dermatol. 2016 Nov;175(5):1070-1072. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27060666
  16. Hou YL, Lee CH Images in Dermatology. Pyoderma Gangrenosum JAMA Dermatol. Published online December 15, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/3491008 https://jamanetwork.com/journals/jamadermatology/fullarticle/2787273
  17. Ashchyan HJ, Nelson CA, Stephen S et al Neutrophilic dermatoses: Pyoderma gangrenosum and other bowel- and arthritis-associated neutrophilic dermatoses. J Am Acad Dermatol. 2018 Dec;79(6):1009-1022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29653213 Review.

Patient information

Pyoderma gangrenosum patient information